Clinical development of a dendritic-cell vaccine therapy for acute myeloid leukaemia

Project Information

AML-VACCiN

Grant agreement ID: 667713

DOI 10.3030/667713

Project closed

EC signature date 9 December 2015

Start date 1 January 2016

End date 30 September 2020

Funded under

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Total cost € 8 278 716,25

EU contribution € 6 001 482,00

Coordinated by

STICHTING AMSTERDAM UMC
Netherlands

Deliverables

Other (1)

Document providing the logo and templates for a uniform corporate look

Websites, patent fillings, videos etc. (2)

Press release on the outcome of the interim analysis on effect DCP-001 vaccination on MRD
Press release on the completion of the Phase IIb study

Documents, reports (2)

Cumulative Expenditure report

Cumulative expenditure report required upon activation of Article 205 GA due to the existence of a 24 month reporting period to be submitted by 30 September 2020

Communication and dissemination plan